RARE vs SVRA
RARE: Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases. SVRA: Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
Side-by-side fundamentals
| Metric | RARE | SVRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $27.65 | $5.65 | |
| Market cap as of 2026-07-23 | $2.8B | $1.2B | |
| PEG as of 2026-07-23 | -1.23 | -0.81 | RARE lower |
| Net margin as of 2026-07-23 | -91.0% | -4253.9% | RARE higher |
| Gross margin as of 2026-07-23 | +83.6% | +100.0% | SVRA higher |
| Operating margin as of 2026-07-23 | -83.8% | -4150.0% | RARE higher |
| ROE as of 2026-07-23 | -414.2% | -87.2% | SVRA higher |
| ROA as of 2026-07-23 | -45.7% | -66.4% | RARE higher |
| Debt / equity as of 2026-07-23 | 90.54 | 0.17 | SVRA lower |
| Revenue growth (YoY) as of 2026-07-23 | +13.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +22.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 0.28 | 0.25 | |
| 1-year return as of 2026-07-22 close | +4.6% | +134.4% | SVRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.